Edition:
United Kingdom

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

143.95EUR
11:31am BST
Change (% chg)

€-0.05 (-0.03%)
Prev Close
€144.00
Open
€144.25
Day's High
€144.70
Day's Low
€143.30
Volume
45,935
Avg. Vol
374,192
52-wk High
€171.20
52-wk Low
€74.48

Latest Key Developments (Source: Significant Developments)

Pharnext Updates On Collaboration with Galapagos
Monday, 9 Sep 2019 

Sept 9 (Reuters) - PHARNEXT SA ::PHARNEXT AND GALAPAGOS SUCCESSFULLY ACHIEVED THEIR RESEARCH AND DEVELOPMENT COLLABORATION.COLLABORATION AIMS TO GENERATE A NEW DRUG DEVELOPMENT PIPELINE IN SEVERAL THERAPEUTIC AREAS FOR GALAPAGOS.COLLABORATION HAS LED TO IDENTIFICATION OF INTERESTING NOVEL COMBINATIONS THAT ARE NOW IN ADVANCED PRECLINICAL TESTING.  Full Article

BRIEF-Galapagos Files Application To Initiate Insolvency Proceedings
Sunday, 25 Aug 2019 

Corrects throughout to show the alerts were from Galapagos SA, not from Galapagos NV :GALAPAGOS-FILED APPLICATION TO INITIATE INSOLVENCY PROCEEDINGS WITH COMPETENT LOCAL COURT OF DÜSSELDORF DUE TO PENDING ILLIQUIDITY & OVER-INDEBTEDNESS.GALAPAGOS-BY WAY OF ORDER OF 23 AUGUST 2019 LOCAL COURT OF DÜSSELDORF APPOINTED FRANK KEBEKUS AS PRELIMINARY INSOLVENCY ADMINISTRATOR OF ASSETS OF CO.GALAPAGOS-NO ENFORCEMENT OVER SHARES IN & PREFERRED EQUITY CERTIFICATES OF GALAPAGOS BIDCO MAY OCCUR DURATION OF PRELIMINARY INSOLVENCY PROCEEDINGS.GALAPAGOS-ALSO ANNOUNCES IT NO LONGER ENVISAGES IMPLEMENTING TRANSACTION PREVIOUSLY ANNOUNCED & AS DEFINED IN, CO'S ANNOUNCEMENT ON 7 JUNE 2019.COMPANY WITHDREW ITS INSTRUCTIONS TO ITS COUNSEL TO PROCEED WITH APPLICATION IN ENGLISH HIGH COURT.CO OPPOSED MAKING OF ANY ADMINISTRATIVE ORDER IN ENGLISH HIGH COURT.GALAPAGOS - DISMISSED MATTHEW CHARLES TURNER, AND JOHN SAMUEL KEEN, AS DIRECTORS WITH EFFECT AS OF DATE HEREOF.APPOINTED JAN BAYER AS SOLE DIRECTOR OF COMPANY, WITH EFFECT AS OF DATE HEREOF.  Full Article

Galapagos Says H1 Loss Per Share Eur 1.76
Thursday, 25 Jul 2019 

July 25 (Reuters) - Galapagos NV ::H1 LOSS PER SHARE EUR 1.76 .STRONG CLINICAL PROGRESS IN H1 AND TRANSFORMATIVE COLLABORATION WITH GILEAD ANNOUNCED.H1 OPERATING LOSS OF EUR 97.6 MILLION.SAYS H1 REVENUES EUR 108.5MLN VERSUS EUR 101.9 MILLION.FINANCIAL GUIDANCE FOR FULL YEAR 2019 OPERATIONAL CASH BURN BETWEEN EUR 320 AND EUR 340 MILLION IS UNCHANGED.GILEAD INTENDS TO FILE FILGOTINIB FOR APPROVAL IN RA IN EUROPE IN Q3 2019.H1 OPERATING LOSS 97.6 MILLION EUROS VERSUS LOSS OF 65.8 MILLION EUROS.H1 NET FINANCIAL RESULT 1.8 MILLION EUROS VERSUS 6.9 MILLION EUROS.  Full Article

Proteostasis Therapeutics Announces Management Changes And Appointments
Tuesday, 23 Jul 2019 

July 23 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES MANAGEMENT CHANGES AND APPOINTMENTS.PROTEOSTASIS THERAPEUTICS INC - GEOFFREY S. GILMARTIN, MD, MMSC, TO SUCCEED PO-SHUN LEE, MD AS CHIEF MEDICAL OFFICER.PROTEOSTASIS THERAPEUTICS INC - PO-SHUN LEE TO REMAIN A CONSULTANT FOR COMPANY.PROTEOSTASIS THERAPEUTICS INC - ANDREY BELOUS APPOINTED AS SENIOR MEDICAL DIRECTOR, JOINING FROM GALAPAGOS NV.  Full Article

Gilead And Galapagos Enter Into Transformative Research And Development Collaboration
Sunday, 14 Jul 2019 

July 14 (Reuters) - Galapagos Nv ::GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION.GILEAD TO MAKE $3.95 BILLION UPFRONT PAYMENT AND $1.1 BILLION EQUITY INVESTMENT.GILEAD GAINS ACCESS TO GALAPAGOS' DIFFERENTIATED DRUG DISCOVERY PLATFORM AND CURRENT AND FUTURE PIPELINE OUTSIDE OF EUROPE.INVESTMENT ENABLES GALAPAGOS TO EXPAND AND ACCELERATE RESEARCH AND CLINICAL PROGRAMS.GALAPAGOS GAINS BROADER COMMERCIALIZATION ROLE FOR FILGOTINIB IN EUROPE AND AGREES TO SHARE EQUALLY IN FUTURE DEVELOPMENT COSTS.GILEAD AGREES TO 10-YEAR STANDSTILL.GILEAD SCIENCES AND GALAPAGOS ENTERED INTO A 10-YEAR GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION.GALAPAGOS WILL USE PROCEEDS TO EXPAND AND ACCELERATE ITS RESEARCH AND DEVELOPMENT PROGRAMS.GILEAD AND GALAPAGOS HAVE AGREED TO AMEND CERTAIN TERMS IN AGREEMENT GOVERNING FILGOTINIB.CO TO HAVE GREATER INVOLVEMENT IN FILGOTINIB'S GLOBAL STRATEGY AND PARTICIPATE MORE BROADLY IN COMMERCIALIZATION OF PRODUCT IN EUROPE.GILEAD'S EQUITY INVESTMENT WILL CONSIST OF A SUBSCRIPTION FOR NEW GALAPAGOS SHARES AT A PRICE OF EUR 140.59 PER SHARE.EQUITY INVESTMENT WILL INCREASE GILEAD'S STAKE FROM APPROXIMATELY 12.3% TO 22% OF ISSUED AND OUTSTANDING SHARES IN GALAPAGOS.CO INTENDS TO SEEK SHAREHOLDER APPROVAL TO ISSUE TWO WARRANTS ALLOWING GILEAD TO FURTHER INCREASE ITS OWNERSHIP TO UP TO 29.9% OF CO.DEAL ALSO INCLUDES 10-YEAR STANDSTILL RESTRICTING GILEAD'S ABILITY TO SEEK TO ACQUIRE GALAPAGOS OR INCREASE ITS STAKE BEYOND 29.9% OF CO.  Full Article

Galapagos: Gilead Plans To Submit New Drug Application For Filgotinib To FDA
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Galapagos NV ::GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR.FILGOTINIB IS AN INVESTIGATIONAL AGENT AND NOT APPROVED ANYWHERE GLOBALLY.COMPANY DISCUSSED WITH AGENCY PHASE 3 FINCH STUDIES, AS WELL AS ONGOING PHASE 2 MANTA SAFETY STUDY.AS RESULT OF THIS DISCUSSION, A PATH FORWARD HAS BEEN ESTABLISHED TO SUBMIT NDA FOR FILGOTINIB AS TREATMENT FOR RHEUMATOID ARTHRITIS IN 2019.  Full Article

Galapagos NV Net Loss Of EUR 48.7 Million In Q1
Thursday, 25 Apr 2019 

April 25 (Reuters) - Galapagos NV ::GALAPAGOS NV - GROUP REVENUES OF EUR 40.9 MILLION OF Q1.GALAPAGOS NV - NET LOSS OF EUR 48.7 MILLION IN Q1.GALAPAGOS NV - RETAIN GUIDANCE FOR OPERATIONAL CASH BURN BETWEEN EUR 320 - 340 MILLION IN 2019.GALAPAGOS NV - WILL CONTINUE RECRUITMENT IN OUR PROPRIETARY ISABELA AND NOVESA TRIALS, AND PLAN TO FULLY RECRUIT OUR PINTA TRIAL.  Full Article

Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study
Wednesday, 24 Apr 2019 

April 24 (Reuters) - GALAPAGOS NV ::ANNOUNCED ON TUESDAY INITIATION OF GECKO.GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.RECRUITMENT WILL TAKE PLACE IN THE U.S. AND CANADA.STUDY IS INTENDED TO SERVE AS AN IND (INVESTIGATIONAL NEW DRUG) OPENER WITH THE U.S. FDA.  Full Article

Galapagos FY Revenue Up At 317.8 Million Euros
Friday, 22 Feb 2019 

Feb 22 (Reuters) - GALAPAGOS NV ::SAID ON THURSDAY FY REVENUE EUR 317.8 MLN VS EUR 155.9 MLN YR AGO.FY OPERATING LOSS EUR 44.8 MLN VS LOSS OF EUR 89.8 MLN YR AGO.FY NET LOSS EUR 29.3 MLN VS LOSS OF EUR 115.7 MLN YR AGO.CASH, CASH EQUIVALENTS AND RESTRICTED CASH EUR 1.29 BLN AT END-2018 VS EUR 1.15 BLN YR AGO.EXPECTS TO RUN OVER 40 CLINICAL TRIALS THIS YEAR.WE WILL EXPAND OUR COMMERCIAL ORGANIZATION FURTHER AS WE GEAR UP FOR A POTENTIAL MARKET LAUNCH OF FILGOTINIB IN 2020 -CFO.IN 2019 AIMS TO REPORT TOPLINE RESULTS FOR THE FINCH 1 AND FINCH 3 TRIALS IN RA IN Q1.IN 2019 PLANS TO FULLY RECRUIT OUR PHASE 2 PINTA STUDY FOR OUR FULLY PROPRIETARY IPF COMPOUND GLPG1205 AS WELL AS OUR ROCCELLA STUDY IN OA.FOR MOR106 WE PLAN TO START A PHASE 2 TRIAL IN ATD WITH MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS.IN H2 2019 EXPECT PRIMARY ANALYSIS OF THE IGUANA PHASE 2 TRIAL IN ATD AND TOPLINE RESULTS OF SUBCUTANEOUS PHASE 1 BRIDGING STUDY.WE EXPECT AN OPERATIONAL CASH BURN BETWEEN €320 AND €340 MILLION IN 2019.  Full Article

Galapagos S.A. Bob Rajan Joins The Board Of Directors
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - GALAPAGOS SA ::BOB RAJAN JOINS THE BOARD OF DIRECTORS.  Full Article

CORRECTED-BRIEF-Galapagos Files Application To Initiate Insolvency Proceedings

* GALAPAGOS-FILED APPLICATION TO INITIATE INSOLVENCY PROCEEDINGS WITH COMPETENT LOCAL COURT OF DÜSSELDORF DUE TO PENDING ILLIQUIDITY & OVER-INDEBTEDNESS